Glaukos Corporation (GKOS) Tops Q4 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. PINS
4. COIN
5. RDDT
6. FSLR
7. FND
8. RBLX
9. GILD
10. SNDK

Go back to Glaukos Corporation (GKOS) Tops Q4 EPS by 6c

Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results

February 22, 2022 4:05 PM EST

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key highlights include:

Net sales of $73.2 million in Q4 2021. Glaucoma net sales of $57.1 million and Corneal Health net sales of $16.2 million in Q4 2021. Gross margin of approximately 77% and non-GAAP gross margin of approximately 85% in Q4 2021. Operating expenses of $74.2 million and non-GAAP... More